We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer
Read MoreHide Full Article
Xencor, Inc. (XNCR - Free Report) announced that it has entered into a research collaboration and commercialization agreement with The University of Texas MD Anderson Cancer Center to develop novel CD3 bispecific antibody therapies for the potential treatment of cancer.
Per the agreement, Xencor will have an exclusive option to license worldwide rights to develop/commercialize potential new medicines which are formed from this collaboration. Xencor is also entitled to receive a portion of future payments received by MD Anderson for any product cropping up from the collaboration which is not licensed by Xencor already.
Per the press release, the strategic deal will leverage Xencor’s innovative XmAb technology and expertise in protein engineering along with MD Anderson’s strength in research and discovery of novel therapeutic antibodies.
Shares of Xencor have rallied 26.8% in the past year against the industry’s decrease of 3.8%.
Xencor is engaged in developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
In December 2020, the company entered into a collaboration and license agreement with Janssen, a wholly owned subsidiary of Johnson & Johnson (JNJ - Free Report) , to develop novel CD28 bispecific antibodies for the treatment of prostate cancer.
Xencor received an upfront payment of $50 million and is eligible to receive potential milestone payments and royalties on net sales if a product is commercialized from this deal.
Also, in November 2020, Xencor along with Incyte (INCY - Free Report) and Germany’s MorphoSys AG entered into a collaboration deal to evaluate the combination of Monjuvi (tafasitamab), plamotamab and Bristol-Myers’ (BMY - Free Report) Revlimid (lenalidomide), targeting various lymphoma indications.
We note that, Xencor’s plamotamab (CD20 x CD3) is a XmAb bispecific antibody which is currently in a phase I study for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Monjuvi, a CD19-directed antibody, is co-marketed by MorphoSys and Incyte in combination with Revlimid for relapsed or refractory diffuse large B-cell lymphoma in the United States.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer
Xencor, Inc. (XNCR - Free Report) announced that it has entered into a research collaboration and commercialization agreement with The University of Texas MD Anderson Cancer Center to develop novel CD3 bispecific antibody therapies for the potential treatment of cancer.
Per the agreement, Xencor will have an exclusive option to license worldwide rights to develop/commercialize potential new medicines which are formed from this collaboration. Xencor is also entitled to receive a portion of future payments received by MD Anderson for any product cropping up from the collaboration which is not licensed by Xencor already.
Per the press release, the strategic deal will leverage Xencor’s innovative XmAb technology and expertise in protein engineering along with MD Anderson’s strength in research and discovery of novel therapeutic antibodies.
Shares of Xencor have rallied 26.8% in the past year against the industry’s decrease of 3.8%.
Xencor is engaged in developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
In December 2020, the company entered into a collaboration and license agreement with Janssen, a wholly owned subsidiary of Johnson & Johnson (JNJ - Free Report) , to develop novel CD28 bispecific antibodies for the treatment of prostate cancer.
Xencor received an upfront payment of $50 million and is eligible to receive potential milestone payments and royalties on net sales if a product is commercialized from this deal.
Also, in November 2020, Xencor along with Incyte (INCY - Free Report) and Germany’s MorphoSys AG entered into a collaboration deal to evaluate the combination of Monjuvi (tafasitamab), plamotamab and Bristol-Myers’ (BMY - Free Report) Revlimid (lenalidomide), targeting various lymphoma indications.
We note that, Xencor’s plamotamab (CD20 x CD3) is a XmAb bispecific antibody which is currently in a phase I study for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Monjuvi, a CD19-directed antibody, is co-marketed by MorphoSys and Incyte in combination with Revlimid for relapsed or refractory diffuse large B-cell lymphoma in the United States.
Zacks Rank
Xencor currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>